Stimcell Energetics, Inc. (STME)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| Operating profit | $m | -1 | -1 | ||||||
| Net profit | $m | -1 | -1 | -1 | -0 | -0 | -1 | -1 | -1 |
| EPS reported | $ | -0.03 | -0.04 | ||||||
| Operating cashflow per share | $ | -0.01 | -0.02 | ||||||
| Capex per share | $ | 0.00 | 0.00 | ||||||
| FCF per share | $ | -0.01 | -0.02 | ||||||
| Free cash flow | $m | -0 | -0 | ||||||
| Net debt | $m | 0 | 1 | ||||||
| Book value equity | $m | -1 | -2 | ||||||
| Book value per share | $ | -0.06 | -0.08 | ||||||
| Number of shares | m | 19.84 | 20.89 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | -7.64 | -5.67 | ||||||
| P/S LTM | x | 0.00 | 0.00 | ||||||
| P/FCF LTM | x | -67.25 | -27.95 | ||||||
| EV/EBITDA LTM | x | -18.88 | -34.24 | ||||||
| EV/Sales LTM | x | 0.00 | 0.00 | ||||||
| Earnings Yield LTM | % | -5.95% | -23.54% | ||||||
| FCF Yield | % | -1.49% | -3.58% | ||||||
| Quality | |||||||||
| ROE | % | +45.44% | +60.42% | ||||||
| ROIC | % | -3.33% | +1.85% | ||||||
| Operating margin | % | 0.00% | 0.00% | ||||||
| Gross margin | % | 0.00% | 0.00% | ||||||
| FCF/Sales | % | - | - | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | - | - | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -0.31 | -0.44 | ||||||
| Net Debt/EBITDA | x | -0.84 | -2.64 | ||||||
| EBIT/Net interest | x | -13.20 | -8.36 | ||||||
| Net debt/market cap | % | +4.82% | +20.50% | ||||||
| Net debt/Equity | x | -0.36 | -0.46 | ||||||
| Gross debt/equity | x | -0.37 | -0.46 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
StimCell Energetics Inc. is a biotechnology company focused on the research, development, and market introduction of both therapeutic and non-therapeutic solutions. These products are intended to benefit individuals in the United States who are managing conditions such as diabetes, Parkinson's disease, hypertension, neuropathy, and issues with kidney function. The company's primary product line is the eBalance system, which comprises two versions: the eBalance Pro System, designed for clinical application by healthcare practitioners, and the eBalance Home System, created for personal use to promote overall well-being and alleviate pain. Both systems are operated via the eBalance Console, a central control unit that offers three distinct pre-programmed microcurrent algorithms: one for general wellness, another for pain relief, and a 'dual' mode that combines both. Additionally, these eBalance products aim to provide temporary relief for discomfort in various body parts, including the shoulders, waist, back, neck, arms, and legs. Established in 2010, the company initially operated under the name Cell MedX Corp. before officially rebranding as StimCell Energetics Inc. in November 2024. Its corporate headquarters are located in Vancouver, Canada.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Not enough data to calculate KvantraRank
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
StimCell Energetics Inc. is a biotechnology company focused on the research, development, and market introduction of both therapeutic and non-therapeutic solutions. These products are intended to benefit individuals in the United States who are managing conditions such as diabetes, Parkinson's disease, hypertension, neuropathy, and issues with kidney function. The company's primary product line is the eBalance system, which comprises two versions: the eBalance Pro System, designed for clinical application by healthcare practitioners, and the eBalance Home System, created for personal use to promote overall well-being and alleviate pain. Both systems are operated via the eBalance Console, a central control unit that offers three distinct pre-programmed microcurrent algorithms: one for general wellness, another for pain relief, and a 'dual' mode that combines both. Additionally, these eBalance products aim to provide temporary relief for discomfort in various body parts, including the shoulders, waist, back, neck, arms, and legs. Established in 2010, the company initially operated under the name Cell MedX Corp. before officially rebranding as StimCell Energetics Inc. in November 2024. Its corporate headquarters are located in Vancouver, Canada.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free